Shield Therapeutics (LSE:STX) has begun a Phase II clinical trial in Japan evaluating ACCRUFeR® (ferric maltol) as a potential treatment for Pulmonary Arterial Hypertension (PAH). The study, led by partner MEDLEAP Pharma, is intended to pave the way for a Phase III programme and prospective regulatory filings targeted for 2028. This marks an important step for ACCRUFeR®, addressing the complex needs of PAH patients who often struggle with long-term iron supplementation, and could position the therapy as a key option within this therapeutic area.
The company’s near-term outlook is shaped by strong technical momentum in its share performance, although substantial financial challenges—including persistent losses and constrained cash flow—continue to weigh on overall sentiment. A negative P/E ratio and absence of dividend yield further limit valuation appeal.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company focused on innovative treatments for iron deficiency, with or without anemia. Its flagship product, ACCRUFeR®/FeRACCRU® (ferric maltol), is an oral iron therapy distributed across the U.S., Europe, and Asia through a network of strategic partnerships.
Leave a Reply